Effectiveness of neoadjuvant radiation therapy in muscle-invasive bladder cancer

Cover Page

Cite item


Aim. To evaluate results of bimodal (preoperative radiotherapy + cystectomy) and only surgical treatment in patients with muscle-invasive bladder cancer.

Methods. A retrospective cohort observational study of patients with muscle-invasive bladder cancer from 2006 to 2012 was conducted. Continuous sampling was used. Patients who received radiation therapy in the preoperative period before cystectomy (25 patients) composed the main group, the patients who underwent surgery alone (167 patients) composed the control group.

Results.. 9 of the 25 patients, who underwent neoadjuvant external-beam radiotherapy before cystectomy, died, the overall survival rate during follow-up was 64.0%. In the group of patients who underwent cystectomy alone, the survival rate was 48.5%. We analyzed the survival rate depending on various criteria or prognostic factors. Factors such as age (under 65 years), male gender, degree of differentiation G2, disease stage (II and III as compared with stage IV), lymph nodes negative status are relatively favorable for disease prognosis, and patients survival rates were significantly higher when using neoadjuvant external beam radiotherapy.

Conclusion. The effectiveness of neoadjuvant treatment (radiotherapy) followed by cystectomy for bladder cancer in some situations may have a positive effect; the tumor degree of differentiation, the regional lymph nodes state, clinical stage and age have a prognostic value irrespective of the therapy method.

About the authors

N S Nurgaliev

Kazakh Research and Scientific Institute of Oncology and Radiology

Author for correspondence.
Email: nurgaliyev.ns@gmail.com

E I Ishkinin

Kazakh Research and Scientific Institute of Oncology and Radiology

Email: nurgaliyev.ns@gmail.com


  1. Каприн А.Д., Костин А.А. Современные возможности диагностики и лечения больных раком мочевого пузыря. Леч. врач. 2003; (7): 40-44.
  2. Cowan N.G., Chen Y., Downs T.M. et al. Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv. Urol. 2014. 746298. Epub 2014 May 28. http://dx.doi.org/10.1155/2014/746298
  3. Efstathiou J.A., Bae K., Shipley W.U. et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J. Clin. Oncol. 2009; 27 (25): 4055-4061. http://dx.doi.org/10.1200/JCO.2008.19.5776
  4. Hermans T.J., Fransen van de Putte E.E., Horenblas S. et al. Perioperative treatment and radical cystectomy for bladder cancer - a population based trend analysis of 10,338 patients in the Netherlands. Eur. J. Cancer. 2015; 17 (54): 18-26.
  5. Jemal A., Bray F., Center M.M. et al. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69. http://dx.doi.org/10.3322/caac.20107
  6. Koga F., Kihara K., Fujii Y. et al. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study. BJU Int. 2009; 104 (2): 189-194. http://dx.doi.org/10.1111/j.1464-410X.2008.08297.x
  7. Koga F., Kihara K., Yoshida S. et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int. 2012; 109 (6): 860-866. http://dx.doi.org/10.1111/j.1464-410X.2011.10425.x
  8. Mak R.H., Hunt D., Shipley W.U. et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J. Clin. Oncol. 2014; 32 (34): 3801-3809. http://dx.doi.org/10.1200/JCO.2014.57.5548
  9. Ploussard G., Daneshmand S., Efstathiou J.A. et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur. Urol. 2014; 66 (1): 120-137. http://dx.doi.org/10.1016/j.eururo.2014.02.038
  10. Smith Z.L., Christodouleas J.P., Keefe S.M. et al. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013; 112 (1): 13-25. http://dx.doi.org/10.1111/j.1464-410X.2012.11762.x

© 2016 Nurgaliev N.S., Ishkinin E.I.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies